Crispr Therapeutics AG has made an announcement about its proposed convertible senior notes offering. The company plans to offer $350 million aggregate principal amount of its convertible senior notes due 2031 in a private offering. There is also an expectation to grant the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of the notes.
The notes will be senior, unsecured obligations of the company and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2026. The notes will mature on March 1, 2031, unless earlier converted, redeemed, or repurchased.
The company intends to use the net proceeds from the offering for general corporate purposes. The offer and sale of the notes and the common shares deliverable upon conversion of the notes have not been registered under the securities act or any other securities laws.
Founded over a decade ago, Crispr Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The company has evolved from a pioneering research-stage organization into an industry leader and has marked a historic milestone with the approval of Casgevy®, the world's first Crispr-based therapy approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
The company is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine, and rare diseases. It continues to expand its leadership in gene editing through the development of Syntase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction.
Crispr Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. Crispr Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, Crispr Therapeutics, Inc., and R&D operations based in Boston, Massachusetts, and San Francisco, California. Following these announcements, the company's shares moved -1.29%, and are now trading at a price of $53.51. If you want to know more, read the company's complete 8-K report here.
